serpil heger

Systematical search for new mechanisms of action, therapy and drug trends in the scientific‐pharmaceutical and medical research environment, which hold substantial innovation potential for diabetes patients- Development of an extensive overview of the diabetes market environment after 2015 - Worldwide planning of turnover, sales and quantity for potential new pharmaceuticals-Development and implementation of vision, mission and tactics in key strategic areas.

Global device project leadership and overall accountability for all device development projects within the PCSK9 family - Submission and launch preparation - Definition of LCM strategies

Group lead of a team responsible for multiple combination products and device development projects from different drug and device development areas. Focusing also on the definition and development of strategic device technology platforms: Budget of > € 20M per year/ 9 direct reports

Overall accountability for all device development projects within the Sanofi-Regeneron alliance: Budget of > € 15M per year/4 direct reports

Multiple drug/device combination project leadership: Budget of > € 5M per project and year/ 2 direct reports / International project teams of > 40 team members

Development of the pediatric investigation plan strategy for Sanofi’s blockbuster Insulin Lantus - Overall leadership and accountability for development of a reusable half unit device (Haselmeier) : Budget of > € 5 M /1 direct report

Device development and worldwide launch preparation of the disposable Insulin pen Solostar for Lantus & Apidra: Budget of € 7 M /cross-functional teams > 25 members - Development of an electro-mechanical device

- Development and launch preparation of the blood glucose monitoring meter ACCU-CHEC Compact Plus & customized test strip development: Project team of > 20 team members

- Project management of public relation projects including event management, customer relations and corporate identity